Key result
Review highlights antiviral candidates targeting structural and non-structural proteins in the Enterovirus 71 lifecycle.
Why the study?
Enterovirus 71 can cause severe neurological complications and death, particularly in infants, but there are no approved antivirals or valid vaccines.
Interfering with EV71 virus-host interactions and viral proteome functions offers numerous targets for developing urgently needed antiviral strategies.
No approved EV71 antivirals exist; leaves open multiple protein targets for hypothesis-generating development.
Enterovirus 71 (EV71) is a pathogen of concern, especially after its reemergence in most parts of Asia. This virus can lead to severe neurological complications and death, particularly in infants. There are no approved antivirals to prevent or treat EV71 infections, or valid vaccines. EV71 relies on precise virus-host interactions that take place during the viral life cycle, and interference with these offers numerous targets for antiviral strategies that are explored herein. We highlight known antiviral candidates and also alternative avenues to develop novel drugs.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) conducted a review in Enterovirus 71 (EV71) infection. Antiviral candidates targeting EV71 was evaluated. This review highlights various antiviral candidates targeting the Enterovirus 71 lifecycle and viral proteome, including inhibitors of structural and non-structural proteins.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: